Thermo Fisher Scientific Aktie News

Bought 18,686 shares; estimated trade size ~$8.70 million based on quarterly average price for Q3 2025 Transaction represents 0.2% of fund's 13F reportable assets under management Post-trade position: 104,361 shares valued at $50.62 million as of September 30, 2025 Now accounts for 1.19% of the fund's U.S. equity holdings, outside its top five positions

FRANKFURT, Germany--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, will showcase its latest flexible solutions to help boost efficiency and scale in biopharmaceutical manufacturing at every stage of drug development during CPHI Frankfurt 2025 (October 28–30, booth #5.1A8, Hall 5.1). Leaders from across the organization will participate in a series of panel ...

Thermo Fisher is well-positioned for continued revenue growth driven by easing pharma uncertainty, reshoring, and recovering clinical research trends. Margins should expand through operating leverage, productivity gains from the PPI system, and AI-driven efficiency improvements. Trading slightly below historical valuation despite improving fundamentals, the stock offers attractive upside potent...

We purchased several new fund holdings across various sectors. Sempra has been shifting its strategic focus from its highly regulated California operations to its growing presence in Texas. Regeneron in our view has a strong balance sheet and a robust product pipeline.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduced the Thermo Scientific™ Orbitrap Exploris™ EFOX Mass Detector, the industry's first high-resolution accurate mass (HRAM) Orbitrap system designed specifically for environmental and food safety laboratories. The new system addresses urgent global challenges around food and water qualit...

The company successfully concluded its $4,000 million repurchase program, creating value for shareholders. In Q3 2024, Thermo Fisher's revenues increased by 4.94%, a symptom that the company has improved its growth outlook. The Fed reduced the U.S. interest rates to 4.22% in September 2025, which will incentivize investments in the biopharma industry.

Thermo Fisher Scientific stock has rebounded strongly as tariff and policy fears proved overstated, with shares up 30% since the prior low. Thermo raised 2025 revenue and EPS guidance, driven by sales growth and margin expansion. Sales are now growing year-on-year across all segments. Recent acquisitions support the US reshoring trend but are expected to be slightly dilutive until 2027.  Long-t...

Thermo Fisher Scientific Inc. (NYSE:TMO ) Q3 2025 Earnings Call October 22, 2025 8:30 AM EDT Company Participants Rafael Tejada - Vice President of Investor Relations Marc Casper - Chairman, President & CEO Stephen Williamson - Senior VP & CFO Conference Call Participants Michael Ryskin - BofA Securities, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Nephron ...